A clinical chemistry enzyme selection matrix converts an assay concept into a structured comparison. It does not choose a supplier automatically. Instead, it forces the development team to define the measurand, enzyme role, reaction architecture, cofactors, specimen, signal, and failure risks before ranking candidates.
This page is designed as a working reference. The first matrix connects common analytes with representative enzyme systems. The following matrices translate platform requirements and raw-material data into a qualification plan. Each row should be adapted to the intended measurement procedure.
Our product offerings: Clinical Chemistry & General Metabolic Testing Enzymes
| Measurand | Representative Enzyme System | Detection Mode | Critical Selection Risk |
|---|---|---|---|
| Glucose | Hexokinase–G6PDH, glucose oxidase–peroxidase, or cofactor-specific GDH | NAD(P)H, color, or electrochemical signal | Oxygen, alternate sugars, hematocrit, cofactor and platform fit |
| HbA1c by enzymatic route | Protease and fructosyl-peptide oxidase plus total-hemoglobin method | Peroxide-linked color or other indicator | Proteolysis, glycated-fragment specificity, hemoglobin variants and traceability |
| Total cholesterol | Cholesterol esterase, cholesterol oxidase, peroxidase | Colorimetric peroxide response | Complete ester hydrolysis, surfactant compatibility, reducing substances |
| Triglycerides | Lipase, glycerol kinase, glycerol-3-phosphate oxidase, peroxidase | Colorimetric peroxide response | Free glycerol, ATP/magnesium, lipase substrate breadth |
| Creatinine | Creatininase, creatinase, sarcosine oxidase, peroxidase | Colorimetric peroxide response | Endogenous creatine/sarcosine, cascade blank, traceability |
| Urea | Urease and GLDH | NAD(P)H decrease | Ammonia contamination, cofactor blank, specimen handling |
| Uric acid | Uricase and peroxidase | Colorimetric peroxide response | Ascorbate and other reducing interferents |
| Lactate | Lactate oxidase or L-lactate dehydrogenase | Peroxide, NADH, or electrode signal | Stereospecificity, post-collection change, oxygen or equilibrium |
| Ammonia | GLDH with alpha-ketoglutarate and NAD(P)H | NAD(P)H decrease | Contamination, rapid sample change, nonspecific cofactor loss |
| Homocysteine | Reduction plus enzyme conversion or cycling system | Cofactor or color signal | Total-form recovery, cysteine cross-response, processing delay |
| NEFA | Acyl-CoA synthetase, acyl-CoA oxidase, peroxidase | Colorimetric peroxide response | Fatty-acid spectrum, CoA/ATP stability, thiol effects |
| Total bile acids | 3-alpha-hydroxysteroid dehydrogenase with cycling or indicator reaction | Nicotinamide-cofactor-linked signal | Bile-acid species response and cycling proportionality |
| Measured Enzyme | Key Reagent Components | Method-Control Variable | Important Matrix Risk |
|---|---|---|---|
| ALT | Alanine, 2-oxoglutarate, LDH, NADH, optional PLP | PLP status and nonlimiting LDH | Hemolysis and endogenous pyruvate |
| AST | Aspartate, 2-oxoglutarate, MDH, NADH, optional PLP | PLP status and nonlimiting MDH | Hemolysis and extrahepatic AST |
| ALP | Phosphate substrate, alkaline buffer, magnesium and zinc | pH, temperature, metal availability | Chelating anticoagulants and isoforms |
| GGT | Gamma-glutamyl donor and acceptor | Substrate blank and acceptor concentration | Optical interference and nonspecific clinical interpretation |
| CK | Creatine phosphate, ADP, HK, G6PDH, NADP+, activator | Adenylate kinase suppression and coupling reserve | Hemolysis, muscle source, macro-CK |
| LDH | Lactate or pyruvate and NAD(H) | Reaction direction, substrate level, linear rate | Hemolysis and broad tissue distribution |
| Amylase | Defined oligosaccharide substrate and possibly alpha-glucosidase | Substrate purity, calcium, chloride, lag | Salivary activity, macroamylase, chelators |
| Lipase | Lipid or synthetic ester substrate, surfactants, optional colipase | Interfacial chemistry and nonspecific esterase response | Lipemia and substrate-dependent method differences |
| Platform | Enzyme Requirements | Formulation Requirements | Verification Emphasis |
|---|---|---|---|
| Automated liquid clinical chemistry | Defined activity, low blank, rapid kinetics, analyzer timing fit | Onboard stability, preservative and surfactant compatibility | Precision, linearity, carryover, calibration and HIL interference |
| Manual or microplate colorimetry | Broad timing tolerance and stable endpoint | Simple reconstitution and wavelength compatibility | Operator timing, plate uniformity, path-length effects |
| Dry chemistry | Drying tolerance and rapid reactivation | Uniform deposition, moisture control, packaging | Rehydration, reflectance, humidity and lot uniformity |
| Electrochemical POCT strip | Mediator and electrode compatibility, fast apparent kinetics | Immobilization, membrane transport, dry stability | Hematocrit, oxygen, electroactive substances, sample fill |
| Optical POCT cartridge | High signal in small volume and short time | Microfluidic mixing, bubble control, material compatibility | Temperature, sample volume, device-to-device variation |
| Continuous biosensor | Operational stability and controlled electron transfer | Anti-fouling membrane, enzyme retention, biocompatible interface | Drift, response time, biofouling, calibration and long-duration performance |
A scoring system should separate mandatory requirements from trade-offs. A candidate that fails a must-have specificity or cofactor requirement should not win because it has high activity. Weighting should be defined before results are reviewed.
| Criterion | Suggested Evidence | Example Weight | Pass/Fail Trigger |
|---|---|---|---|
| Identity and catalytic role | Sequence/source, EC class, reaction and cofactor documentation | Mandatory | Wrong reaction or undefined identity |
| Substrate specificity | Cross-reactant panel in buffer and finished assay | High | Bias exceeds predefined limit |
| Activity under assay conditions | Normalized internal method and dose-response | High | Cannot meet timing or range |
| Matrix tolerance | Native-specimen recovery and interference studies | High | Uncontrollable specimen-dependent bias |
| Formulation stability | Real-time, in-use, stress and diagnostic response | High | Fails planned shelf-life margin |
| Side activities and blank | Targeted impurity assays and finished-reagent blank | High | Uncorrectable background or cofactor consumption |
| Lot consistency | Multiple lots tested with common controls and specimens | Medium to high | Lot effect exceeds allowable variation |
| Supply and documentation | Scale, packaging, change control, traceability, technical data | Medium | Cannot support intended manufacturing or compliance |
For a whole-blood glucose strip, a candidate with excellent liquid activity but poor drying recovery should rank below a moderately active enzyme with strong mediator compatibility, low alternate-sugar response, and stable post-drying performance. For an ALT liquid reagent, substrate specificity is largely defined by the patient enzyme; the main supplier-enzyme decision may involve LDH coupling capacity, side activity, NADH blank, and onboard stability.
The matrix should therefore be used at the enzyme-role level, not copied once for an entire kit. A recognition enzyme, coupling enzyme, and reporter enzyme can require different weights within the same assay.
| Stage | Minimum useful evidence | Decision enabled |
|---|---|---|
| Paper screen | Reaction role, EC class, source, cofactor, nominal activity method, purity format, and available lots | Exclude candidates incompatible with the proposed chemistry |
| Bench screen | Normalized activity, dose-response plateau, blank, specificity panel, pH profile, and representative matrix recovery | Rank candidates under intended-use conditions |
| Prototype | Finished-reagent precision, measuring range, interference, accelerated stress, and component compatibility | Select formulation and backup candidate |
| Qualification | Multiple lots, certificate review, change-control expectations, scale-representative material, and real-time stability initiation | Approve a controlled raw material |
| Lifecycle | Incoming trends, lot bridging, deviations, stability surveillance, and supplier-change assessment | Maintain performance after launch |
| Early observation | Risk it may indicate | Next experiment |
|---|---|---|
| High certificate activity but weak finished-assay response | Activity-method mismatch, inhibition, poor cofactor pairing, or access limitation | Compare normalized dose curves in supplier and assay conditions |
| Increasing enzyme no longer improves the high sample | Substrate, cofactor, oxygen, reporter, or detector limitation | Titrate each non-enzyme component and inspect reaction traces |
| Good buffer performance but variable patient recovery | Matrix inhibition, interferent response, or analyte accessibility | Test native specimens, dilution behavior, and downstream intermediates |
| Prototype passes wet but fails after drying | Loss during deposition, drying, rehydration, or mediator contact | Measure pre-dry, post-dry, and extracted functional activity |
| Mean response is stable but precision worsens | Heterogeneous enzyme, incomplete mixing, layer nonuniformity, or particulate formation | Map within-run position, vial, strip, and deposition-zone effects |
Every score should point to a test result, document, or justified assumption. A blank field and an unfavorable result are different: the former represents uncertainty, while the latter represents demonstrated risk. Teams can penalize missing evidence explicitly instead of giving an untested candidate a neutral score.
